Classifying breast cancers by their estrogen receptor status (estrogen receptor positive (ER+) or estrogen receptor negative (ER-)) is done to assist in the selection of appropriate therapies-some ER+ cancers respond favorably to hormone blockers while ER- cancers do not. The gene discussed is ESR1; the disease is cancer.